查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016876

血管支架市場：2026-2032年全球市場預測（依產品類型、適應症、輸送方式、材料、成分及最終用戶分類）

Stent Grafts Market by Product Type, Indication, Delivery Mechanism, Material, Configuration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血管支架市場價值將達到 4.592 億美元，到 2026 年將成長至 4.9501 億美元，到 2032 年將達到 8.082 億美元，複合年成長率為 8.41%。

主要市場統計數據
基準年 2025 4.592億美元
預計年份：2026年 4.9501億美元
預測年份 2032 8.082億美元
複合年成長率 (%) 8.41%

本文生動地介紹了臨床進步、器械工程和經濟壓力如何改變血管支架市場的結構。

血管支架融合了血管治療、器械工程和醫療保健系統策略，為各種動脈瘤和周邊血管疾病提供了一種持久有效的替代開放性手術。過去十年，器械設計、影像引導植入技術和手術全期管理方面的進步擴大了支架移植物適用患者群體，並縮短了手術時間。同時，材料科學的進步提高了支架的耐久性和生物相容性。因此，在可靠的註冊數據和持續的器械改進的支持下，臨床團隊越來越傾向於將血管內治療作為複雜解剖結構的首選治療方法。

器械設計、材料、手術流程和保險公司審查方面的突破，如何為血管支架的採用和價值實現帶來巨大變化？

技術進步、臨床實踐和採購行為的改變正在推動一系列根本性變革，重新定義血管支架的發展、應用和報銷方式。血管內治療正從一種小眾替代方案發展成為主流策略。影像技術的進步、經皮入路的普及以及開窗和分叉技術的成熟加速了這一進程，使得以往被認為仿單標示外血管支架治療的複雜主動脈病變也能得到治療。因此，器械發展藍圖優先考慮低輪廓輸送、模組化適應性和增強的密封機制，以降低內漏風險。

該評估評估了 2025 年貿易政策變化如何促進了整個血管支架移植生態系統的供應鏈重組、籌資策略重新評估和策略在地化。

2025年美國實施的關稅累積效應對供應鏈、籌資策略和製造商的在地化決策產生了實際的連鎖反應。進口關稅的提高和全球零件供應的集中化促使製造商重新評估其關鍵零件的籌資策略，例如鎳鈦合金框架、ePTFE和聚酯接枝材料以及輸送系統聚合物。作為應對措施，一些上游供應商加快了在北美地區的產能擴張，而另一些供應商則修改契約，選擇性地轉嫁成本。這導致短期內價格承壓，並引發了關於長期供應商多元化的討論。

將產品類型、適應症、醫療保健環境、給藥平台、材料和成分與策略性臨床和商業重點聯繫起來的詳細細分分析。

透過對產品、適應症、最終用戶、給藥機制、材料和配置等各個維度進行詳細檢驗，我們可以識別出能夠指南臨床應用和商業策略的特定領域趨勢。依產品類型分類，市場分為“主動脈器械”和“周邊血管器械”，其中主動脈器械又細分為針對“腹主動脈瘤”和“胸主動脈瘤”的治療方法。每個子領域都有其獨特的解剖結構、手術流程和器械相關複雜性，這些都會影響設計重點和臨床培訓。按適應症分類，市場分為“動脈瘤修復”和“周邊血管疾病”，其中“動脈瘤修復”領域又細分為腹部和胸部適應症。這反映了各個治療領域不同的實證依據和監管路徑。

區域趨勢和差異化的市場進入方式與世界各地不同的監管、臨床和採購實際情況相符。

區域趨勢塑造了產品應用模式、監管預期和供應策略，進而影響短期策略和長期投資。在美洲，微創治療方案在臨床實踐中備受青睞，這得益於先進的影像基礎設施和眾多優質醫療中心的支持，從而加速了複雜主動脈器械的應用。該地區的採購週期受到大規模醫療機構和綜合醫療系統的影響，這些機構和系統優先考慮已證實有效的治療效果和可預測的服務水準。

競爭格局正趨向於整合產品創新、策略聯盟和強力的臨床證據，這些因素能夠推動採購和臨床信心。

產品創新、策略夥伴關係和有針對性的臨床證據項目的整合正在重塑競爭動態，使企業能夠鞏固並擴大其市場地位。市場領導正投資研發新一代輸送系統，以縮小體積並改善導航性能，同時也努力擴展其模組化產品組合，以便在手術過程中進行個人化。同時，專注於材料科學的製造商正在開發專有的移植背襯和密封技術，以解決人們對長期耐久性和降低再次手術率的擔憂。

提供切實可行的策略指導，以增強臨床差異化、供應彈性、客製化商業化和支付方參與度，從而建立長期競爭優勢。

產業領導者應優先考慮平衡的策略，兼顧臨床差異化、供應鏈韌性和商業性精準性，以掌握機會並降低風險。首先，他們應投資於新一代輸送系統和移植材料，以降低手術複雜性和再次手術風險，並將這些技術進步與針對性臨床項目相結合，從而在具有代表性的患者群體中產生真實世界數據（REW）。其次，他們應加快供應鏈多元化進程，具體措施包括：認證關鍵零件的二級供應商、探索近岸外包方案，以及協商能夠應對銷售波動而不影響利潤率的靈活合約。

綜合混合方法研究框架，結合專家訪談、文獻整合、監管審查和供應鏈映射，以檢驗策略見解。

本研究途徑結合了第一手和第二手調查，以確保研究結果基於真實的臨床環境，並經過各領域專家檢驗。第一手調查包括對血管外科醫生、介入性放射科醫生、醫院採購經理和器械工程師進行結構化訪談，以了解他們對器械性能、手術流程和採購重點的實際觀點。透過與專家的訪談，研究人員針對不同醫療環境中的臨床應用障礙、理想的器材特性和操作限制進行了主題分析。

簡潔扼要的結論整合了技術、臨床和操作方面的要求，這些要求將決定未來幾年血管支架的成功和廣泛應用。

總之，血管支架領域正經歷一場意義深遠的變革時期，其驅動力包括技術進步、臨床路徑的演變以及供應鏈和政策趨勢的轉變。這些因素要求製造商在輸送系統、材料和模組化方面不斷創新，同時也需要提供更可靠的真實世界數據（REW），並與醫療服務提供者的工作流程更緊密地整合。醫療服務提供者則透過調整診療路徑、投資影像和混合技術以及做出以結果為導向的採購決策來應對這些變革。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：血管支架市場：依產品類型分類

  • 主動脈
    • 腹部主動脈血管瘤
    • 胸主動脈瘤
  • 外圍

第9章：血管支架市場：依適應症分類

  • 動脈瘤修復
    • 腹部
    • 胸部
  • 周邊血管疾病

第10章：血管支架市場：依輸送機制分類

  • 球囊擴張型
  • 自膨脹

第11章：血管支架市場：依材料分類

  • ePTFE
  • 聚酯纖維

第12章：血管支架市場：依組成

  • 分叉型
  • 分支類型
  • 直的

第13章：血管支架市場：依最終用戶分類

  • 門診手術中心
  • 醫院

第14章：血管支架市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：血管支架市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章血管支架市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國血管支架市場

第18章：中國血管支架市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bentley InnoMed GmbH
  • Boston Scientific Corporation
  • Braile Biomedica
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • CORCYM, Inc.
  • Cryolife Inc.
  • Edwards Lifesciences Corporation
  • Endospan Ltd.
  • InSitu Technologies Inc.
  • Jotec GmbH
  • Kawasumi Laboratories, Inc.
  • LeMaitre Vascular, Inc.
  • Lifetech Scientific（Shenzhen）Co., Ltd.
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-03147A7F3DEB

The Stent Grafts Market was valued at USD 459.20 million in 2025 and is projected to grow to USD 495.01 million in 2026, with a CAGR of 8.41%, reaching USD 808.20 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 459.20 million
Estimated Year [2026] USD 495.01 million
Forecast Year [2032] USD 808.20 million
CAGR (%) 8.41%

A dynamic introduction describing why clinical advances, device engineering and economic pressures are reshaping the stent graft landscape

Stent grafts sit at the convergence of vascular therapy, device engineering, and health system strategy, representing a durable alternative to open surgical repair for a range of aneurysmal and peripheral vascular pathologies. Over the last decade, progress in device design, imaging-guided deployment techniques, and perioperative management has broadened candidate eligibility and shortened procedural times, while improved materials science has enhanced durability and biocompatibility. Consequently, clinical teams increasingly view endovascular solutions as first-line interventions in complex anatomies, supported by robust registry data and iterative device improvements.

At the same time, healthcare providers and manufacturers face mounting pressures to deliver value through demonstrable outcomes and controlled costs. Hospitals and ambulatory surgical centers must balance capital investment in imaging and hybrid operating rooms against procedure volumes and reimbursement variability. Manufacturers must navigate an evolving regulatory environment while advancing modularity, low-profile delivery systems, and tailored graft configurations that address anatomical variability. Taken together, these forces frame a competitive landscape where clinical efficacy, operational efficiency, and supply chain resilience determine strategic positioning and commercial success.

How breakthroughs in device design, materials, procedural pathways and payer scrutiny are accelerating a step change in stent graft deployment and value delivery

A profound set of transformative shifts is redefining how stent grafts are developed, adopted, and reimbursed, driven by converging advances in technology, clinical practice, and procurement behavior. Endovascular therapy is evolving from a niche alternative to a mainstream strategy, accelerated by better imaging modalities, adoption of percutaneous access, and the maturation of fenestrated and branched technologies that enable treatment of complex aortic segments previously considered unsuitable for endografting. As a result, device roadmaps prioritize low-profile delivery, modular adaptability, and enhanced sealing mechanisms that mitigate endoleak risk.

Concurrently, materials innovation-particularly refinements in ePTFE and polyester graft backings-has improved fatigue resistance and long-term patency while reducing thromboembolic and inflammatory responses. Delivery mechanism innovations, including refinements in both balloon-expandable and self-expandable platforms, are enhancing precision and reducing procedural complications. Moreover, the move toward patient-specific solutions, including custom fenestrations and branched constructs, is driving closer collaboration between manufacturers, imaging vendors, and clinical centers.

Operationally, the rise of ambulatory surgical centers for select peripheral interventions is reshaping care pathways, pressuring hospitals to demonstrate value-add for complex cases. In parallel, payers and health technology assessment bodies are increasingly scrutinizing real-world outcomes, compelling manufacturers to invest in post-market surveillance, registries, and health economics analyses. These shifts collectively favor agile organizations that can couple clinical evidence generation with manufacturing scalability and targeted market access strategies.

Assessing how trade policy changes in 2025 catalyzed supply chain realignment, procurement reevaluation, and strategic localization across the stent graft ecosystem

The cumulative consequences of tariffs implemented in 2025 in the United States have created tangible ripples across supply chains, procurement strategies, and manufacturer localization decisions. Increased import duties combined with global component concentration have made manufacturers reassess sourcing strategies for critical components such as nitinol frames, ePTFE and polyester graft materials, and delivery system polymers. In response, some upstream suppliers accelerated capacity expansion within North America while others restructured contracts to pass through costs selectively, creating short-term pricing pressure and longer-term conversations about supplier diversification.

These tariff-driven dynamics pushed hospital procurement teams to re-evaluate vendor portfolios and total cost of ownership calculations, emphasizing predictable supply and service as much as unit price. Clinical teams confronted intermittent device backorders and lead-time variability that underscored the importance of multi-vendor strategies and inventory buffering for scheduled elective repairs. Additionally, manufacturers recalibrated market access approaches, increasing emphasis on localized manufacturing, nearshoring critical components, and renegotiating distributor terms to maintain competitive positioning.

Regulatory and compliance teams faced increased scrutiny of traceability and origin declarations, while strategy functions accelerated analysis of vertically integrated versus contract manufacturing models. Overall, tariffs acted as a catalyst for supply-chain modernization and strategic realignment, prompting both short-term operational adaptations and longer-term investments in regional manufacturing, supplier resilience, and contractual flexibility to mitigate future policy and trade volatility.

Deep segmentation analysis connecting product types, indications, care settings, delivery platforms, materials and configurations to strategic clinical and commercial priorities

A nuanced examination of the market by product, indication, end user, delivery mechanism, material, and configuration reveals differentiated dynamics that inform clinical adoption and commercial strategy. Based on product type the landscape bifurcates into Aortic and Peripheral devices, with Aortic solutions further delineated into treatments targeting Abdominal Aneurysm and Thoracic Aneurysm; each subdomain carries distinct anatomical, procedural, and device complexity considerations that influence design priorities and clinical training. Based on indication the segmentation splits into Aneurysm Repair and Peripheral Vascular Disease, with the Aneurysm Repair stream further differentiated into Abdominal and Thoracic indications, reflecting divergent evidence bases and regulatory pathways for each therapy area.

Based on end user the channels include Ambulatory Surgical Centers and Hospitals, and this divergence affects device selection, allowable inventory models, and the level of on-site imaging and hybrid operating room infrastructure required for complex aortic repairs. Based on delivery mechanism devices are categorized across Balloon Expandable and Self Expandable systems, a dichotomy that drives choices around radial force, conformability, and deployment precision. Based on material the market is studied across ePTFE and Polyester graft backings, each presenting trade-offs in porosity, handling, and long-term tissue integration. Finally, based on configuration the product set includes Bifurcated, Branched, and Straight constructs, with branched and bifurcated designs addressing junctional anatomy and complex arch or iliac involvement. Integrating these segmentation layers yields actionable insights for portfolio prioritization, clinical education targeting, and evidence-generation investments tailored to specific procedure types and care settings.

Regional dynamics and differentiated market entry approaches that reconcile diverse regulatory, clinical and procurement realities across global territories

Regional dynamics are shaping adoption patterns, regulatory expectations, and supply strategies in ways that influence both near-term tactics and long-term investments. In the Americas clinical practice favors minimally invasive treatment pathways supported by advanced imaging infrastructure and a concentration of centers of excellence, which accelerates uptake of complex aortic devices. Procurement cycles in this region are influenced by large institutional buyers and integrated health systems that place a premium on demonstrated outcomes and predictable service levels.

In Europe, Middle East & Africa market participants operate within a heterogeneous regulatory and reimbursement landscape that demands adaptable commercial approaches; reimbursement variability and diverse hospital capabilities make country-level evidence and localized health economic arguments essential. In addition, the region presents opportunities for regional manufacturing hubs and cross-border distributor models that can reduce lead times.

The Asia-Pacific region exhibits rapidly expanding procedural volumes driven by demographic shifts and increasing investments in tertiary care capacity, with several markets showing strong demand for both conventional and advanced fenestrated or branched solutions. However, supply chain considerations, regulatory approval timelines, and local competitive entrants lead manufacturers to pursue tailored entry strategies, including partnerships, licensing arrangements, and phased product rollouts that reflect local clinical workflows and procurement preferences. These regional contours underscore the necessity of differentiated commercial models, regulatory preparedness, and targeted clinical engagement to unlock growth and sustain access.

Competitive ecosystems are converging around integrated product innovation, strategic alliances, and robust clinical evidence that drive procurement and clinical trust

Competitive dynamics are being reshaped by a blend of product innovation, strategic partnerships, and targeted clinical evidence programs that enable firms to defend and expand their positions. Market leaders are investing in next-generation delivery systems that reduce profile and increase navigability, while also expanding modular portfolios that allow for intra-procedural customization. At the same time, manufacturers with a strong focus on materials science are developing proprietary graft backings and sealing technologies to address long-term durability concerns and reduce reintervention rates.

Strategic collaborations between device companies and imaging or software providers are accelerating development of integrated planning and navigation tools that improve sizing accuracy and reduce procedural variability. Mergers, licensing deals, and contract manufacturing arrangements continue to redistribute capabilities, with some companies prioritizing in-house manufacturing to control quality and supply reliability, while others leverage specialist partners to scale production quickly. Clinical trial design is shifting toward pragmatic registry-based evidence and real-world outcomes to satisfy payers and regulatory bodies, and companies that can demonstrate robust longitudinal data have a comparative advantage when negotiating hospital formularies and reimbursement pathways.

Finally, service models such as procedural support, training academies, and value-added aftermarket services are increasingly important differentiators, enabling companies to establish deeper relationships with high-volume centers and to embed their technologies within care pathways.

Actionable strategic guidance to strengthen clinical differentiation, supply resilience, tailored commercialization, and payer engagement for long-term competitive advantage

Industry leaders should prioritize a balanced strategy that addresses clinical differentiation, supply resilience, and commercial precision to capture opportunity and mitigate risk. First, invest in next-generation delivery systems and graft materials that demonstrably reduce procedural complexity and reintervention risk, and couple these technical advances with targeted clinical programs that generate real-world evidence in representative patient cohorts. Second, accelerate supply chain diversification by qualifying secondary suppliers for critical components, exploring nearshoring options, and negotiating flexible contracts that allow for volume variability without exposing margins.

Third, tailor go-to-market approaches by care setting; for ambulatory surgical centers, emphasize low-profile, single-use procedural kits and streamlined inventory models, while for hospitals focus on hybrid-room compatibility, clinical training, and outcomes-based partnerships. Fourth, develop modular commercial offerings that integrate device solutions with imaging and planning software to reduce friction in sizing and deployment. Fifth, proactively engage payers and health technology assessment bodies with transparent longitudinal outcomes and cost-effectiveness analyses to secure stable reimbursement. Lastly, cultivate strategic alliances with clinical centers of excellence and regional distributors to accelerate adoption while ensuring robust post-market surveillance and customer support.

A comprehensive mixed-methods research framework combining expert interviews, literature synthesis, regulatory review and supply-chain mapping to validate strategic insights

The research approach integrates both primary and secondary methods to ensure findings are grounded in clinical reality and validated by domain experts. Primary research included structured interviews with vascular surgeons, interventional radiologists, hospital procurement leads, and device engineers to capture frontline perspectives on device performance, procedural workflows, and procurement priorities. These expert conversations informed thematic analysis around clinical adoption barriers, preferred device attributes, and operational constraints across different care settings.

Secondary research consisted of a systematic review of peer-reviewed clinical literature, regulatory guidance documents, device labeling, and procedural registries to triangulate safety and efficacy signals and to understand device lifecycle considerations. Supply-chain analysis leveraged trade and customs data supplemented by supplier disclosures to map critical component dependencies and manufacturing footprints. Throughout the process, findings were cross-validated by an internal expert panel and subjected to methodological checks for bias and representativeness. Where applicable, sensitivity analyses were conducted to assess the robustness of strategic implications under alternative trade, regulatory, and clinical adoption scenarios.

A concise conclusion synthesizing technological, clinical and operational imperatives that will determine stent graft success and adoption in the coming years

In conclusion, the stent graft domain is experiencing a period of substantive transformation driven by technological advances, evolving clinical pathways, and shifting supply-chain and policy dynamics. These forces are encouraging manufacturers to pursue innovations in delivery systems, materials, and modular configurations while also demanding stronger real-world evidence and closer alignment with provider workflows. Healthcare providers are responding by adapting care pathways, investing in imaging and hybrid capabilities, and emphasizing outcome-driven procurement decisions.

Trade policy changes and regional disparities have underscored the importance of supply resilience and localized strategies, and they have prompted organizations to balance cost considerations with service reliability and inventory management. Going forward, success will accrue to firms and health systems that integrate clinical excellence with operational robustness, prioritize patient-centered outcomes, and adopt flexible commercial models that reflect the heterogeneity of regional regulatory and reimbursement environments. Continuous investment in evidence generation, clinician training, and strategic partnerships will be indispensable to sustaining adoption and delivering long-term value to patients and healthcare stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Stent Grafts Market, by Product Type

  • 8.1. Aortic
    • 8.1.1. Abdominal Aneurysm
    • 8.1.2. Thoracic Aneurysm
  • 8.2. Peripheral

9. Stent Grafts Market, by Indication

  • 9.1. Aneurysm Repair
    • 9.1.1. Abdominal
    • 9.1.2. Thoracic
  • 9.2. Peripheral Vascular Disease

10. Stent Grafts Market, by Delivery Mechanism

  • 10.1. Balloon Expandable
  • 10.2. Self Expandable

11. Stent Grafts Market, by Material

  • 11.1. ePTFE
  • 11.2. Polyester

12. Stent Grafts Market, by Configuration

  • 12.1. Bifurcated
  • 12.2. Branched
  • 12.3. Straight

13. Stent Grafts Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Hospitals

14. Stent Grafts Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Stent Grafts Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Stent Grafts Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Stent Grafts Market

18. China Stent Grafts Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. B. Braun Melsungen AG
  • 19.6. Becton, Dickinson and Company
  • 19.7. Bentley InnoMed GmbH
  • 19.8. Boston Scientific Corporation
  • 19.9. Braile Biomedica
  • 19.10. Cardinal Health, Inc.
  • 19.11. Cook Medical LLC
  • 19.12. CORCYM, Inc.
  • 19.13. Cryolife Inc.
  • 19.14. Edwards Lifesciences Corporation
  • 19.15. Endospan Ltd.
  • 19.16. InSitu Technologies Inc.
  • 19.17. Jotec GmbH
  • 19.18. Kawasumi Laboratories, Inc.
  • 19.19. LeMaitre Vascular, Inc.
  • 19.20. Lifetech Scientific (Shenzhen) Co., Ltd.
  • 19.21. Medtronic PLC
  • 19.22. MicroPort Scientific Corporation
  • 19.23. Terumo Corporation
  • 19.24. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL STENT GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STENT GRAFTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL STENT GRAFTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL STENT GRAFTS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL STENT GRAFTS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL STENT GRAFTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STENT GRAFTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL STENT GRAFTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STENT GRAFTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES STENT GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA STENT GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STENT GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STENT GRAFTS MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STENT GRAFTS MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STENT GRAFTS MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STENT GRAFTS MARKET SIZE, BY ABDOMINAL ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STENT GRAFTS MARKET SIZE, BY ABDOMINAL ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STENT GRAFTS MARKET SIZE, BY ABDOMINAL ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STENT GRAFTS MARKET SIZE, BY THORACIC ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STENT GRAFTS MARKET SIZE, BY THORACIC ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STENT GRAFTS MARKET SIZE, BY THORACIC ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STENT GRAFTS MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STENT GRAFTS MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STENT GRAFTS MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STENT GRAFTS MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STENT GRAFTS MARKET SIZE, BY ABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STENT GRAFTS MARKET SIZE, BY ABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STENT GRAFTS MARKET SIZE, BY THORACIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STENT GRAFTS MARKET SIZE, BY THORACIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STENT GRAFTS MARKET SIZE, BY THORACIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STENT GRAFTS MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL STENT GRAFTS MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL STENT GRAFTS MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL STENT GRAFTS MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STENT GRAFTS MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STENT GRAFTS MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STENT GRAFTS MARKET SIZE, BY SELF EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STENT GRAFTS MARKET SIZE, BY SELF EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STENT GRAFTS MARKET SIZE, BY SELF EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STENT GRAFTS MARKET SIZE, BY EPTFE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STENT GRAFTS MARKET SIZE, BY EPTFE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STENT GRAFTS MARKET SIZE, BY EPTFE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STENT GRAFTS MARKET SIZE, BY POLYESTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STENT GRAFTS MARKET SIZE, BY POLYESTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STENT GRAFTS MARKET SIZE, BY POLYESTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STENT GRAFTS MARKET SIZE, BY BIFURCATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STENT GRAFTS MARKET SIZE, BY BIFURCATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STENT GRAFTS MARKET SIZE, BY BIFURCATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STENT GRAFTS MARKET SIZE, BY BRANCHED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STENT GRAFTS MARKET SIZE, BY BRANCHED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STENT GRAFTS MARKET SIZE, BY BRANCHED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STENT GRAFTS MARKET SIZE, BY STRAIGHT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STENT GRAFTS MARKET SIZE, BY STRAIGHT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STENT GRAFTS MARKET SIZE, BY STRAIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL STENT GRAFTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL STENT GRAFTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL STENT GRAFTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL STENT GRAFTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STENT GRAFTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STENT GRAFTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STENT GRAFTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS STENT GRAFTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA STENT GRAFTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL STENT GRAFTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GCC STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GCC STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 147. GCC STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. GCC STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 149. GCC STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 150. GCC STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 151. GCC STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. G7 STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 174. G7 STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. G7 STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 176. G7 STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 177. G7 STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 178. G7 STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. NATO STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. NATO STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NATO STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 183. NATO STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 185. NATO STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 186. NATO STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 187. NATO STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL STENT GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES STENT GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA STENT GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA STENT GRAFTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA STENT GRAFTS MARKET SIZE, BY AORTIC, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA STENT GRAFTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA STENT GRAFTS MARKET SIZE, BY ANEURYSM REPAIR, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA STENT GRAFTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA STENT GRAFTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA STENT GRAFTS MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA STENT GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)